Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewCarfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsDual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.The presence of Epstein-Barr virus significantly impacts the transcriptional profile in immunodeficiency-associated Burkitt lymphoma.An evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesMEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activationThe Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphomaAnti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors.The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses.
P2860
Q24597424-8AA3C22C-4D7E-4360-8969-2D68F45C6F9CQ27304386-87A50C77-A0E8-42AE-998F-1FA5FC05B633Q35005087-1BA7373A-5428-440D-A39B-34145794B3F8Q35007061-72D6C69E-6E2D-4404-B50D-708066FACAEFQ35072963-4F0E3080-BFA7-4596-AE7C-1139460AF90EQ35434111-92A512AB-08DA-4C99-9F71-94CA059C94EEQ35711180-D61A7918-8F34-4D27-9A83-1A4263580488Q36696524-3E94F070-B1D4-4623-8D84-74476E44F38AQ37031859-FCBFDC84-B44A-4085-A395-9181027A1723Q37084564-805B840E-11C8-440E-A1FA-8A4E769402DCQ37171616-2F172FA4-E9CB-4335-A2D5-C686E7E8D186Q38161760-477B2056-E3AD-4BC2-98A6-C478AC33F152Q38845179-8EDE66DD-3E3F-40CF-9CBC-9B510C7604B6Q38999607-9FFD467F-5C3A-40CB-85AB-368A5F0006D5Q39036088-CBD8F32C-431D-4D00-8E4F-26E330E829C0Q39926284-7A859577-FD93-49FE-AB55-B3F26FCA4F3FQ42061450-4FE2C1B7-F676-4103-9ED8-07DC3231F7EAQ55364601-74028B01-7795-41D4-B826-D851FE2D9CAB
P2860
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@ast
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@en
type
label
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@ast
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@en
prefLabel
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@ast
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@en
P2093
P2860
P1476
Obatoclax interacts synergisti ...... BCL cells in vitro and in vivo
@en
P2093
Derick Peterson
Dmitry Lembersky
Elisa Attkisson
Girija Dasmahapatra
Hiral Patel
Jonathan W Friedberg
Minkyeong P Son
Richard I Fisher
Steven Grant
P2860
P304
P356
10.1158/1535-7163.MCT-12-0021
P50
P577
2012-03-12T00:00:00Z